Acute Effect of Transcutaneous Electrical Nerve Stimulation in Heart Failure (TensIC)

Federal University of Health Science of Porto Alegre

Status

Unknown

Conditions

Improvement of Cardiovascular Autonomic Control

Reduction of Levels of Catecholamines

Treatments

Other: transcutaneous electrical nerve stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT01252407

TensIC

Details and patient eligibility

About

The purpose of this study is to determine acute effect the transctutaneous electrical nerve stimulation in sympathetic and parassympathetic system in individuals with heart failure.

Full description

Heart failure (HF) is the inability of the heart to maintain adequate levels of blood supply to tissues. In recent years there has been an increased prevalence of heart failure (HF), in Brazil there are about two million people diagnosed with HF and 240,000 new cases per year. Thus, the IC constitutes the most serious problem now and in the fields of cardiology and public health. Sympathetic activity is increased and correlates with a worse prognosis and survival in these patients. Currently, the pharmacological blockade of the sympathetic system by chronic use of beta-blockers are commonly used to treat hyperactivity, but these interventions have side effects. The transcutaneous electrical nerve stimulation (TENS) has been used successfully to control pain in different clinical conditions and may be a noninvasive strategy to reduce drug and not the severity of increased sympathetic.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Possess stable heart failure grade II or III according to NYHA;
Ejection fraction <40% determined by echocardiography;
Having no change in drug therapy one month before being included in the study;
There have been Myocardial Infarction (AMI) three months before study entry;

Exclusion criteria

Patients with grade IV heart failure according to NYHA;
Acute respiratory;
Unstable angina;
Ventricular arrhythmia, unstable until three months before the start of the study;
Pacemaker;
Active smoking;
Diabetes mellitus;
And fever or infectious disease.